An article by the Associated Press (AP) published Oct. 17 considers, “Are 3D mammograms better than standard 2D imaging for catching advanced [breast] cancers?” The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), discussed in the article and managed daily by the American College of Radiology® (ACR®) Center for Research and Innovation, intends to find out.
The National Cancer Institute-funded TMIST study — one of the most diverse cancer screening trials in history — already has nearly 93,000 of the planned 128,000 participants enrolled. The AP reports, “At the U.S. study sites, 21% of study participants are Black women — that’s higher than a typical cancer treatment study, in which 9% of participants are Black.”
The AP quotes Etta Pisano, MD, FACR, ACR Chief Research Officer, who shared that the study, led by the ECOG-ACRIN Cancer Research Group, “added more international sites to enhance the trial’s diversity, particularly for Hispanic and Asian women.”
For more information, visit acr.org/TMIST.
State Legislative Update: Breast Health Legislation in the States
The 2025 state legislative sessions will be busy with action likely on breast health issues, including numerous bills addressing supplemental and diagnostic coverage without cost sharing to the patient and other key considerations in breast cancer prevention and care.
HRSA Breast Cancer Screening for Average Risk Guideline
The U.S. Department of Health and Human Services Health Resources and Services Administration finalized its proposal for the Breast Cancer Screening for Women at Average Risk guideline.
Read moreACR Comments on Draft HRSA Breast Cancer Screening Recommendations
The American College of Radiology® (ACR®) submitted comments this week on draft recommendations for the Health Resources and Services Administration (HRSA)-supported Women's Preventive Services Guidelines , including for breast cancer screening.
Read more